OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
39
Results
Show all
Save search
Copy query
Show results for
Unknown
(28)
Genomics
(11)
Organisms
Homo sapiens
(11)
Repository
EGA
(11)
Technology Type
Illumina (various), Illumina (Various)
(1)
Affymetrix 6.0, Illumina_670k - Illuminus, Illumina 1.2M
(1)
Publication Date
Release Date
2021
(6)
2022
(5)
2023
(4)
2024
(2)
2015
(2)
2014
(2)
2009
(2)
2025
(1)
2019
(1)
2018
(1)
2013
(1)
2008
(1)
Previous
page
1 / 4
You're on page
1
page
2
page
3
page
4
Next
page
Sort
by:
Relevance
Page size
10
Development and assessment of a novel gold immunochromatographic assay for the diagnosis of schistosomiasis japonica.
Not available
S-EPMC10106775
|
biostudies-literature
Cite
Comparative assessment of the SjSAP4-incorporated gold immunochromatographic assay for the diagnosis of human schistosomiasis japonica.
Not available
S-EPMC10509475
|
biostudies-literature
Cite
PD-1 combination therapy with IL-2 modifies CD8
+
T cell exhaustion program.
Not available
S-EPMC9793890
|
biostudies-literature
Cite
FinnuncorrNLITUK1UK3hap300 - samples
All cases and controls (Hap300)
EGAD00010000298
|
EGA
Cite
FinnuncorrNLITUK3hap550_onlyNBS - samples
NBS control samples only (Hap550)
EGAD00010000290
|
EGA
Cite
FinnuncorrNLITUK1UK3hap300_no1958BC_noNBS - samples
All cases and Finnish, Dutch, Italian control samples (Hap300)
EGAD00010000292
|
EGA
Cite
FinnuncorrNLITUK3hap550_only1958BC - samples
1958BC control samples only (Hap550)
EGAD00010000296
|
EGA
Cite
FinnuncorrNLITUK3hap550_no1958BC_noNBS - samples
All cases and Finnish, Dutch, Italian control samples (Hap550)
EGAD00010000288
|
EGA
Cite
FinnuncorrNLITUK1UK3hap300_onlyNBS - samples
NBS control samples only (Hap300)
EGAD00010000284
|
EGA
Cite
FinnuncorrNLITUK3hap550 - samples
All cases and controls (Hap550)
EGAD00010000286
|
EGA
Cite
Previous
page
1 / 4
You're on page
1
page
2
page
3
page
4
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets